Janus Henderson Group PLC Apellis Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

$188 Billion
Q4 2024

A detailed history of Janus Henderson Group PLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 34,412 shares of APLS stock, worth $661,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,412

Previous 34,412 -0.0%

Holding current value

$661,054

Previous $992,000 10.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $20,062 - $31,467	-527 Reduced 1.51%	34,412 $1.32 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $164,951 - $215,815	-2,978 Reduced 7.85%	34,939 $2.05 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $2,748 - $4,796	-74 Reduced 0.19%	37,917 $2.27 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $41.1 Million - $155 Million	-1,738,914 Reduced 97.86%	37,991 $1.45 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $223 Million - $271 Million	-2,904,577 Reduced 62.04%	1,776,905 $162 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $32.3 Million - $46.5 Million	693,737 Added 17.4%	4,681,482 $309 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $172 Million - $243 Million	3,973,609 Added 28109.85%	3,987,745 $206 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $87,640 - $136,394	-1,958 Reduced 12.17%	14,136 $964,000
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $4,278 - $7,223	122 Added 0.76%	16,094 $728,000
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $2,304 - $3,517	65 Added 0.41%	15,972 $811,000
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $301,682 - $482,456	9,814 Added 161.07%	15,907 $753,000
Q3 2021 Nov 16, 2021	BUY	$31.4 - $69.84 $191,320 - $425,535	6,093 New	6,093 $201,000

Others Institutions Holding APLS

# of Institutions

296

Shares Held

111M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.11B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Apellis Pharmaceuticals, Inc. Transaction History